Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
5
×
biotech
life sciences
national blog main
boston blog main
clinical trials
national top stories
new york blog main
boston top stories
fda
indiana blog main
indiana top stories
national
new york top stories
raleigh-durham blog main
raleigh-durham top stories
alirocumab
alnylam pharmaceuticals
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
evolocumab
inclisiran
merck
novartis
pcsk9
regeneron pharmaceuticals
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
sanofi
seattle blog main
seattle top stories
texas blog main
texas top stories
the medicines company
wisconsin blog main
What
new
5
×
drug
fda
brings
cholesterol
medicines
migraine
wave
acquire
acute
addresses
adults
advantages
agreed
allergan
approval
approved
bar
billion
bio
cash
causes
class
company
compound
condition
deal
decades
drugs
eli
expect
expensive
faces
financial
foe
friday
gamble
giant
giving
healthcare
Language
unset
5
×
Current search:
amgen
×
unset
×
new
×
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)